Anika Therapeutics, Inc.
ANIK
$21.38
$0.703.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.56% | 13.16% | 0.04% | -5.89% | -8.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.56% | 13.16% | 0.04% | -5.89% | -8.15% |
| Cost of Revenue | -17.97% | -7.59% | -11.14% | 20.51% | 35.38% |
| Gross Profit | 47.91% | 29.40% | 8.16% | -19.70% | -29.90% |
| SG&A Expenses | -16.79% | 25.41% | 6.68% | -12.35% | -21.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.85% | 10.05% | -2.38% | 4.76% | -0.41% |
| Operating Income | 189.14% | 8.94% | 752.53% | -3,891.36% | -130.94% |
| Income Before Tax | 185.22% | -24.61% | 1,858.97% | -788.00% | -226.42% |
| Income Tax Expenses | -89.57% | 164.04% | -141.07% | -56.73% | -48.64% |
| Earnings from Continuing Operations | 171.21% | -27.74% | 172.45% | -72.09% | -82.88% |
| Earnings from Discontinued Operations | -- | -- | 92.21% | 103.01% | -72.40% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 183.35% | -3.76% | 101.34% | 92.22% | -4,411.36% |
| EBIT | 189.14% | 8.94% | 752.53% | -3,891.36% | -130.94% |
| EBITDA | 279.57% | 7.36% | 47.12% | -3,619.23% | -1,274.60% |
| EPS Basic | 189.80% | -9.65% | 101.37% | 92.03% | -4,584.75% |
| Normalized Basic EPS | 212.80% | 11.65% | 20.94% | -802.17% | -237.11% |
| EPS Diluted | 184.69% | -8.63% | 101.05% | 92.03% | -4,703.39% |
| Normalized Diluted EPS | 210.84% | 11.65% | 18.12% | -802.17% | -234.05% |
| Average Basic Shares Outstanding | -7.20% | -5.36% | -2.08% | -2.36% | -3.20% |
| Average Diluted Shares Outstanding | -5.51% | -5.36% | 0.31% | -2.36% | -2.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |